Daniel M Altstatt, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Miller Dr, Brownwood, TX 76801 Phone: 325-643-2000 |
News Archive
PlastiPure, a safer-plastics technology company, has announced a partnership with ReliaBrand to license infant feeding, sports bottle, food packaging, and medical products free of harmful chemicals that cause estrogenic activity (EA). Chemicals with EA have been strongly linked to adverse health effects such as birth defects, reproductive cancers, and behavioral and learning disorders. The widely known chemicals BPA and phthalates are only a few of thousands of chemicals suspected to have EA.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers.
CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.
"Uruguay's Congress voted narrowly on Wednesday to legalize abortions during the first 12 weeks of pregnancy, a rare move in largely Catholic Latin America that underscores the country's liberal leanings," Reuters reports.
› Verified 5 days ago